A guide to cancer immunotherapy: from T cell basic science to clinical practice

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621

First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

How regulatory T cells work

Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688

Delivery technologies for cancer immunotherapy

Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,678

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Motzer, R. J., Penkov, K., Haanen, J. B. A. G., Rini, B. I., Albiges, L. K., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Négrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,557

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488

Chimeric antigen receptor T-cell therapy—assessment and management of toxicities

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360

The PD‐1 pathway in tolerance and autoimmunity

Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y. J., Yuan, J. D., Kitano, S., Mu, Z., Rasalan, T. S., Adamow, M. J., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,105

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053

Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831

Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors

Morales, Á., Eidinger, D., & Bruce, A. W. (1976) · The Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,829

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784

The B7–CD28 superfamily

Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Sharma, P., Retz, M. M., Siefker-Radtke, A. O., Baron, A. D., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D. A., Grimm, M., Sergio Bracarda, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,758

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Cohen, E. E. W., Soulières, D., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,737

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730

Cytokine release syndrome

Shimabukuro‐Vornhagen, A., Gödel, P., Subklewe, M. S., Stemmler, H., Schlößer, H., Schlaak, M. S., Kochanek, M., Böll, B., & von Bergwelt‐Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,712

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689

CTLA-4 is a second receptor for the B cell activation antigen B7.

Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685

Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors

Morales, Á., Eidinger, D., & Bruce, A. W. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,528

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

WEIDEN, P. L., Flournoy, N., Thomas, E. D., Prentice, R. L., Fefer, A., Buckner, C. D., & Storb, R. F. (1979) · New England Journal of Medicine · doi:10.1056/nejm197905103001902 · Cited by 1,512

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511

Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signaling Pathway Determines The Outcome Of T Cell Antigen Receptor Occupancy

Mueller, D. L., Jenkins, M. K., & Schwartz, R. H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.002305 · Cited by 1,505

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408

B lymphocytes: how they develop and function

LeBien, T. W., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-02-078071 · Cited by 1,400

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348

A new member of the immunoglobulin superfamily—CTLA-4

Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,307

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285

Toxicities of chimeric antigen receptor T cells: recognition and management

Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272

Using immunotherapy to boost the abscopal effect

Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260

Human T cell development, localization, and function throughout life

Kumar, B. V., Connors, T. J., & Farber, D. L. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.007 · Cited by 1,257

A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Schachter, J., Ribas, A., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,251

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S. C., Chaput, N., Eggermont, A. M. M., Marabelle, A., Soria, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,204

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186

Personalized vaccines for cancer immunotherapy

Şahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,175

Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,081

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,062

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.003 · Cited by 1,047

Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., & White, D. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1159 · Cited by 1,020

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,013

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 1,006

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors

Morales, A. (1976) · The Journal of Urology · Cited by 978

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967

MATURE T LYMPHOCYTE APOPTOSIS—Immune Regulation in a Dynamic and Unpredictable Antigenic Environment

Lenardo, M. J., Chan, F. K.-M., Hornung, F., McFarland, H. F., Siegel, R. M., Wang, J., & Zheng, L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.221 · Cited by 937

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

Krummel, M. F., & Allison, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2533 · Cited by 923

The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses

Carreno, B. M., & Collins, M. A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091101.091806 · Cited by 900

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Wang, J., Sanmamed, M. F., Datar, I. J., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 897

c-Jun overexpression in CAR T cells induces exhaustion resistance

Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891

Memory T Cell Subsets, Migration Patterns, and Tissue Residence

Mueller, S. N., Gebhardt, T., Carbone, F., & Heath, W. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095954 · Cited by 884

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. Μ., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 880

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J., Tran, D. Q., Stoddard, J. L., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 879

Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up

Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869

MHC-II neoantigens shape tumour immunity and response to immunotherapy

Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

Imai, C., Mihara, K., Andreánsky, M., Nicholson, I., Pui, C., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 844

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Ribas, A., Kefford, R. F., Marshall, M. A., Punt, C. J. A., Haanen, J. B. A. G., Mármol, M., Garbe, C., Gogas, H. J., Schachter, J., Linette, G. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 819

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 819

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1051 · Cited by 808

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M. F., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 805

Exploiting the Mutanome for Tumor Vaccination

Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 802

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 786

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772

Immunogenicity of somatic mutations in human gastrointestinal cancers

Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720

Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation

Palacios, E. H., & Weiss, A. (2004) · Oncogene · doi:10.1038/sj.onc.1208074 · Cited by 714

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697

Transcriptional Mechanisms Underlying Lymphocyte Tolerance

Macián, F., Garcia-Cozar, F. J., Im, S., Horton, H. F., Byrne, M. C., & Rao, A. (2002) · Cell · doi:10.1016/s0092-8674(02)00767-5 · Cited by 687

The many important facets of T-cell repertoire diversity

Nikolich‐Žugich, J., Slifka, M. K., & Messaoudi, I. (2004) · Nature reviews. Immunology · doi:10.1038/nri1292 · Cited by 681

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681

Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy

Lo, B., Zhang, K., Lü, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J. M., Marsh, R. A., et al. (2015) · Science · doi:10.1126/science.aaa1663 · Cited by 678

Role of the CD28 receptor in T-cell activation

June, C. H., Ledbetter, J. A., Linsley, P. S., & Thompson, C. B. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90085-n · Cited by 674

CELL TO CELL INTERACTION IN THE IMMUNE RESPONSE

MILLER, J. F. A. P., & Mitchell, G. F. (1968) · The Journal of Experimental Medicine · doi:10.1084/jem.128.4.801 · Cited by 645

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Ghorashian, S., Kramer, A. M., Onuoha, S. C., Wright, G., Bartram, J. L., Richardson, R., Albon, S. J., Castro, F., Popova, B., Villanueva, K., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0549-5 · Cited by 642

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 640

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 633

Therapeutic Cancer Vaccines

Guo, C., Manjili, M. H., Subjeck, J. R., Sarkar, D., Fisher, P. B., & Wang, X. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 621

Reversal of the TCR Stop Signal by CTLA-4

Schneider, H., Downey, J., Smith, A. M., Zinselmeyer, B. H., Rush, C. M., Brewer, J. M., Wei, B. K., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 617

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Reck, M., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Lü, H., Cuillerot, J.-M., & Lynch, T. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 613

Driving CAR T-cells forward

Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613

Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma

Park, J. R., DiGiusto, D. L., Slovak, M. L., Wright, C. L., Naranjo, A., Wagner, J. R., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Saâda-Bouzid, E., Defaucheux, C., Karabajakian, A., Coloma, V. P., Servois, V., Paolettí, X., Even, C., Fayette, J., Guigay, J., Loirat, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx178 · Cited by 599

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

Chmielewski, M. M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 592

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590

The urgent need to recover MHC class I in cancers for effective immunotherapy

Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585

PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma

Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569

Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4

Marengère, L. E. M., Waterhouse, P., Duncan, G. S., Mittrücker, H.-W., Feng, G.-S., & Mak, T. W. (1996) · Science · doi:10.1126/science.272.5265.1170 · Cited by 551

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527

THYMUS-DEPENDENT AREAS IN THE LYMPHOID ORGANS OF NEONATALLY THYMECTOMIZED MICE

PARROTT, D. M. V., de Sousa, M. A. B., & East, J. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.123.1.191 · Cited by 522

Anti-Transgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Re-directed T Cells in Humans

Jensen, M., Popplewell, L., Cooper, L., Digiusto, D., Kalos, M., Ostberg, J., & Forman, S. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 522

The CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune Responses

Coyle, A. J., Lehar, S. M., Lloyd, C. M., Tian, J. Y., Delaney, T. A., Manning, S., Nguyen, T., Burwell, T., Schneider, H., Gonzalo, J. A., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00011-x · Cited by 519

Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses

Nishimura, H. (1998) · International Immunology · doi:10.1093/intimm/10.10.1563 · Cited by 500

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Maio, M., Grob, J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., Garbe, C., Chiarion‐Sileni, V., Testori, A., Chen, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.6018 · Cited by 491

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489

CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells

Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., González, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 485

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Wang, P., Chen, Y., Song, S., Wang, T., Ji, W., Li, S., Liu, N., & Yan, C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00730 · Cited by 479

Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain

Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 469

Establishment of NOD- Pdcd1 -/- mice as an efficient animal model of type I diabetes

Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505497102 · Cited by 450

B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse

Pentcheva‐Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 446

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

Koneru, M., Purdon, T. J., Spriggs, D. R., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 439

Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo

Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

Bielamowicz, K., Fousek, K., Byrd, T. T., Samaha, H., Mukherjee, M., Aware, N., Wu, M.-F., Orange, J. S., Sumazin, P., Man, T., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox182 · Cited by 434

CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location

Harper, K., Balzano, C., Rouvier, É., Mattéi, M., Luciani, M., & Golstein, P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.3.1037 · Cited by 432

Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions

Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., & Kurosawa, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90502-x · Cited by 432

Primary B Cell Immunodeficiencies: Comparisons and Contrasts

Conley, M. E., Dobbs, K., Farmer, D. M., Kilic, S., Paris, K., Grigoriadou, S., Coustan‐Smith, E., Howard, V. C., & Campana, D. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132649 · Cited by 431

CTLA-4 regulates induction of anergy in vivo

Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K., & Sharpe, A. H. (2001) · Immunity · doi:10.1016/s1074-7613(01)00097-8 · Cited by 428

Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR

Valzasina, B., Guiducci, C., Dislich, H., Killeen, N. P., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428

Treg and CTLA-4: Two intertwining pathways to immune tolerance

Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 425

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

Yeku, O., Purdon, T. J., Koneru, M., Spriggs, D. R., & Brentjens, R. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10940-8 · Cited by 420

A guide to manufacturing CAR T cell therapies

Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 403

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C. A., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8099 · Cited by 396

Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

Weinberg, A. D., Rivera, M. M., Prell, R. A., Morris, A. M., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 395

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 387

Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead

Oiseth, S. J., & Aziz, M. S. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.41 · Cited by 386

CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma

Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10067 · Cited by 385

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

Duan, F., Duitama, J., Seesi, S. A., Ayres, C. M., Corcelli, S. A., Pawashe, A., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20141308 · Cited by 383

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382

Therapeutic Targeting of the Tumor Microenvironment

Bejarano, L., Jordão, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,718

Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion

Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570

Clinical and therapeutic relevance of cancer-associated fibroblasts

Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230

Metastasis

Gerstberger, S. C., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 1,010

Nanomedicine in cancer therapy

Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 986

Understanding of Antigen and Phenotypic Plasticity Molecules for the Purpose of Cancer Immunotherapy

Malviya, R., Singh, A. K., & Yadav, D. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003533955-4

Role of T cells in cancer immunotherapy: Opportunities and challenges

Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., et al. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.12.002 · Cited by 148

Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer

Ali, S., Arshad, M., Summer, M., Zulfiqar, M., Noor, S., Nazakat, L., & Javed, M. A. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251324896 · Cited by 10

T Lymphocyte–Based Cancer Immunotherapeutics

Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 27

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211